Gan & Lee gets FDA orphan drug status for GLR2007 in malignant glioma
Gan & Lee Pharmaceuticals has been given orphan drug designation from the US Food and Drug Administration (FDA) for GLR2007 for the treatment of malignant ... Read More
Reyvow CENTURION trial results : Lilly migraine drug succeeds in phase 3 study
Reyvow CENTURION trial results : Eli Lilly and Company (Lilly) said that its migraine drug Reyvow (lasmiditan) has met the co-primary endpoint of a phase ... Read More
SK Biopharmaceuticals launches phase 3 trial of seizures drug cenobamate in Asia
SK Biopharmaceuticals, a South Korean pharma company, has revealed plans to initiate a phase 3 clinical trial for its FDA-approved seizures drug cenobamate in Asia. ... Read More
Bruker acquires Missouri-based life science company Canopy Biosciences
US scientific instruments manufacturer Bruker Corporation has acquired Canopy Biosciences, a life science company engaged in providing high multiplex biomarker imaging for immunology, immuno-oncology, and ... Read More
United Therapeutics appoints Dr Linda Maxwell to board of directors
United Therapeutics, a Maryland biotech company, has appointed head and neck surgeon Dr Linda Maxwell to its board of directors as an independent director. Dr ... Read More
Takeda’s NINLARO fails to meet PFS primary endpoint in TOURMALINE-MM2 trial
Takeda Pharmaceutical said that the Phase 3 TOURMALINE-MM2 trial in newly diagnosed multiple myeloma patients for NINLARO (ixazomib) in addition to lenalidomide and dexamethasone failed ... Read More
Takeda’s NINLARO fails to meet PFS primary endpoint in TOURMALINE-MM2 trial
Takeda Pharmaceutical said that the Phase 3 TOURMALINE-MM2 trial in newly diagnosed multiple myeloma patients for NINLARO (ixazomib) in addition to lenalidomide and dexamethasone failed ... Read More
KA Imaging gets FDA clearance for Reveal X-ray detector
KA Imaging said that Reveal, its portable dual-energy X-ray detector has been granted 510(k) clearance from the US Food and Drug Administration (FDA). The Canadian ... Read More
Evonetix, Analog Devices join forces for third gen DNA synthesis platform
Evonetix, a synthetic biology company, which is engaged in developing a desktop platform for rapid gene synthesis, has entered into a collaboration to develop a ... Read More
Takeda to sell select non-core assets to Cheplapharm for $562m
Takeda Pharmaceutical has agreed to sell a portfolio of certain non-core prescription pharma products sold mainly in Europe and Canada to German pharma company Cheplapharm ... Read More